Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

NCT05760586 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Low-grade Glioma

Interventions

DRUG: Tovorafenib

Sponsor

Day One Biopharmaceuticals, Inc.